Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.
暂无分享,去创建一个
Zahi A Fayad | Valentin Fuster | V. Fuster | D. Rader | Z. Fayad | A. Tall | J. Goldstein | H. Brewer | A. Remaley | R. Rosenson | M. Hellerstein | W. Davidson | Daniel J Rader | H Bryan Brewer | M. Phillips | Alan T Remaley | L. Yvan-Charvet | Robert S Rosenson | W Sean Davidson | James Goldstein | Marc Hellerstein | Xian-Cheng Jiang | Michael C Phillips | George H Rothblat | Alan R Tall | Laurent Yvan-Charvet | Xian-cheng Jiang | G. Rothblat | Michael C. Phillips | H. Brewer | Xian-Cheng Jiang | Xian-Cheng Jiang | Xian-Cheng Jiang | Xian-Cheng Jiang | Michael C. Phillips | Robert S. Rosenson | H. B. Brewer | W. S. Davidson | Daniel J. Rader | Robert S. Rosenson | H. Brewer
[1] M. Hayden,et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.
[2] M. Hayden,et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1 Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M300110-JLR200 , 2003, Journal of Lipid Research.
[3] T. Sand,et al. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[4] D. Rader,et al. Lipases and HDL metabolism , 2002, Trends in Endocrinology & Metabolism.
[5] P. Fitzgerald,et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. , 2010, Journal of the American College of Cardiology.
[6] A. Tall,et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. , 2007, The Journal of clinical investigation.
[7] L. Curtiss,et al. Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma , 2010, Nature Structural &Molecular Biology.
[8] S. Yokoyama,et al. Regulation of Cellular Cholesterol Efflux by Lecithin:Cholesterol Acyltransferase Reaction through Nonspecific Lipid Exchange (*) , 1996, The Journal of Biological Chemistry.
[9] M. Krieger. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. , 1999, Annual review of biochemistry.
[10] Nadine H. Elowe,et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors , 2010, Journal of Lipid Research.
[11] A. Tall,et al. Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[12] D. Steinberg,et al. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Tall,et al. Scavenger Receptor Class B Type I as a Mediator of Cellular Cholesterol Efflux to Lipoproteins and Phospholipid Acceptors* , 1998, The Journal of Biological Chemistry.
[14] D. Sviridov,et al. Dynamics of reverse cholesterol transport: protection against atherosclerosis. , 2002, Atherosclerosis.
[15] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[16] D. Rader,et al. Impact of Combined Deficiency of Hepatic Lipase and Endothelial Lipase on the Metabolism of Both High-Density Lipoproteins and Apolipoprotein B–Containing Lipoproteins , 2010, Circulation research.
[17] D. Rader,et al. The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[18] A. Tall,et al. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL Published, JLR Papers in Press, October 24, 2007. , 2008, Journal of Lipid Research.
[19] A. Tall,et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.
[20] M. Reilly,et al. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. , 2005, The Journal of clinical investigation.
[21] P. Barter,et al. Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[22] T. Egashira,et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. , 2000, Journal of lipid research.
[23] Z. Fayad,et al. Imaging of atherosclerosis. , 2011, Annual review of medicine.
[24] A. Tall,et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.
[25] H. Mabuchi,et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. , 1994, The Journal of clinical investigation.
[26] Albert K Groen,et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. , 2006, The Journal of clinical investigation.
[27] A. Tall,et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.
[28] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[29] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[30] D. Rader,et al. Dose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase , 2003, Circulation.
[31] Yong Ji,et al. Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux* , 1997, The Journal of Biological Chemistry.
[32] T. V. van Berkel,et al. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. , 2004, The American journal of pathology.
[33] D. Sviridov,et al. 5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.
[34] E. Podrez,et al. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. , 2010, Blood.
[35] A. Tall,et al. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. , 1998, Current opinion in structural biology.
[36] D. Rader,et al. A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.
[37] R. F. Hoyt,et al. Hepatic lipase expression in macrophages contributes to atherosclerosis in apoE-deficient and LCAT-transgenic mice. , 2003, The Journal of clinical investigation.
[38] J. Glomset,et al. SOME PROPERTIES OF A CHOLESTEROL ESTERIFYING ENZYME IN HUMAN PLASMA. , 1964, Biochimica et biophysica acta.
[39] Ji-Young Lee,et al. Minimal Lipidation of Pre-β HDL by ABCA1 Results in Reduced Ability to Interact with ABCA1 , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[40] G. Dernick,et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S] , 2010, Journal of Lipid Research.
[41] R. S. Meidell,et al. Effect of Up-regulating Individual Steps in the Reverse Cholesterol Transport Pathway on Reverse Cholesterol Transport in Normolipidemic Mice* , 2001, The Journal of Biological Chemistry.
[42] P. Giral,et al. Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[43] V. Fuster,et al. The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. , 2010, American heart journal.
[44] P. Eacho,et al. Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo * , 2002, The Journal of Biological Chemistry.
[45] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[46] D. Rader,et al. Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[47] A. Tall,et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[48] Jianwen Fang,et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes , 2008, Proceedings of the National Academy of Sciences.
[49] H. Brewer,et al. Cellular localization and trafficking of the human ABCA1 transporter. , 2001 .
[50] M. Nakano,et al. Effects of sphingomyelin on apolipoprotein E- and lipoprotein lipase-mediated cell uptake of lipid particles. , 2003, Biochimica et biophysica acta.
[51] Farhad Rezaee,et al. Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.
[52] K. Moore,et al. Deletion of ABCA1 and ABCG1 Impairs Macrophage Migration Because of Increased Rac1 Signaling , 2011, Circulation research.
[53] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[54] J. Pais de Barros,et al. Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[55] P. Connelly,et al. The role of hepatic lipase in lipoprotein metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[56] E. Fisher,et al. Phospholipid Transfer Protein Deficiency Impairs Apolipoprotein-B Secretion from Hepatocytes by Stimulating a Proteolytic Pathway through a Relative Deficiency of Vitamin E and an Increase in Intracellular Oxidants* , 2005, Journal of Biological Chemistry.
[57] Paul T. Tarr,et al. Characterization of the Human ABCG1 Gene , 2001, The Journal of Biological Chemistry.
[58] D. Rader,et al. The roles of different pathways in the release of cholesterol from macrophages Published, JLR Papers in Press, August 29, 2007. , 2007, Journal of Lipid Research.
[59] W. J. Johnson,et al. Effects of Acceptor Particle Size on the Efflux of Cellular Free Cholesterol (*) , 1995, The Journal of Biological Chemistry.
[60] H. Brewer,et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. , 2001, The Journal of clinical investigation.
[61] Agnes Pasquet,et al. Imaging the vulnerable plaque. , 2011, Journal of the American College of Cardiology.
[62] F. Grosveld,et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. , 2009, Atherosclerosis.
[63] B. Lamarche,et al. Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M400090-JLR200 , 2004, Journal of Lipid Research.
[64] R. F. Hoyt,et al. Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. , 2009, Metabolism: clinical and experimental.
[65] Takeshi Kimura,et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo , 2010, Proceedings of the National Academy of Sciences.
[66] Subramaniam Pennathur,et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.
[67] A. Jonas,et al. Sphingomyelin Inhibits the Lecithin-Cholesterol Acyltransferase Reaction with Reconstituted High Density Lipoproteins by Decreasing Enzyme Binding* , 1996, The Journal of Biological Chemistry.
[68] Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001 .
[69] R. Shamburek,et al. Lecithin Cholesterol Acyltransferase: An Anti- or Pro-atherogenic Factor? , 2011, Current atherosclerosis reports.
[70] Perttu S. Niemelä,et al. Structure of spheroidal HDL particles revealed by combined atomistic and coarse-grained simulations. , 2008, Biophysical journal.
[71] D. Rader,et al. Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation , 2005, Circulation research.
[72] M. Phillips,et al. Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I Published, JLR Papers in Press, January 17, 2006. , 2006, Journal of Lipid Research.
[73] P. Lesnik,et al. Cholesteryl Ester Transfer Protein Expression Partially Attenuates the Adverse Effects of SR-BI Receptor Deficiency on Cholesterol Metabolism and Atherosclerosis* , 2011, The Journal of Biological Chemistry.
[74] R. Brasseur,et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.
[75] J. Parks,et al. Lecithin:Cholesterol Acyltransferase Deficiency Increases Atherosclerosis in the Low Density Lipoprotein Receptor and Apolipoprotein E Knockout Mice* , 2002, The Journal of Biological Chemistry.
[76] G. Franceschini,et al. Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.
[77] D. Mangelsdorf,et al. An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.
[78] M. Reilly,et al. Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis , 2005, PLoS medicine.
[79] Charles C Schwartz,et al. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans Published, JLR Papers in Press, May 16, 2004. DOI 10.1194/jlr.M300511-JLR200 , 2004, Journal of Lipid Research.
[80] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.
[81] A. Waring,et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I , 2008 .
[82] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[83] P. Barter,et al. Impact of Short-Term Administration of High-Density Lipoproteins and Atorvastatin on Atherosclerosis in Rabbits , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[84] Per Leanderson,et al. Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.
[85] Ahmed Tawakol,et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial , 2011, The Lancet.
[86] K. Moore,et al. Selective uptake of HDL cholesteryl esters and cholesterol efflux from mouse peritoneal macrophages independent of SR-BI Published, JLR Papers in Press, August 22, 2006. , 2006, Journal of Lipid Research.
[87] T. V. van Berkel,et al. Scavenger receptor B1 (SR-B1) substrates inhibit the selective uptake of high-density-lipoprotein cholesteryl esters by rat parenchymal liver cells. , 1997, The Biochemical journal.
[88] R. Mahley,et al. Putting cholesterol in its place: apoE and reverse cholesterol transport. , 2006, The Journal of clinical investigation.
[89] G. Anantharamaiah,et al. D-4F, an Apolipoprotein A-I Mimetic Peptide, Inhibits the Inflammatory Response Induced by Influenza A Infection of Human Type II Pneumocytes , 2004, Circulation.
[90] J. Albers,et al. Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity. , 2011, Biochimica et biophysica acta.
[91] John A Wagner,et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.
[92] H. Jansen. Hepatic lipase: Friend or foe and under what circumstances? , 2004, Current atherosclerosis reports.
[93] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[94] M. Jauhiainen,et al. Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA Published, JLR Papers in Press, November 16, 2003. DOI 10.1194/jlr.D300023-JLR200 , 2004, Journal of Lipid Research.
[95] J. Danesh,et al. Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.
[96] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[97] E. Tuzcu,et al. Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) , 2008, Circulation.
[98] A. Vaughan,et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux* , 2009, Journal of Lipid Research.
[99] R. Krauss,et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.
[100] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[101] Scott D Covey,et al. Scavenger Receptor Class B Type I–Mediated Protection Against Atherosclerosis in LDL Receptor–Negative Mice Involves Its Expression in Bone Marrow–Derived Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[102] H. Saito,et al. Mechanism of ATP-binding Cassette Transporter A1-mediated Cellular Lipid Efflux to Apolipoprotein A-I and Formation of High Density Lipoprotein Particles* , 2007, Journal of Biological Chemistry.
[103] J. Heinecke,et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. , 2010, Chemical research in toxicology.
[104] D. Rader,et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.
[105] M. Phillips,et al. High-density lipoprotein heterogeneity and function in reverse cholesterol transport , 2010, Current opinion in lipidology.
[106] A. Tall,et al. The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[107] M. Jauhiainen,et al. Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. , 2007, Biochemistry.
[108] D. Mangelsdorf,et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[109] M. Eriksson,et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. , 1999, Circulation.
[110] W. J. Johnson,et al. Mechanisms and consequences of cellular cholesterol exchange and transfer. , 1987, Biochimica et biophysica acta.
[111] A. Jonas. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. , 1991, Biochimica et biophysica acta.
[112] M. Heller,et al. Mass spectrometry‐based analytical tools for the molecular protein characterization of human plasma lipoproteins , 2005, Proteomics.
[113] A. Vaughan,et al. ABCG1 Redistributes Cell Cholesterol to Domains Removable by High Density Lipoprotein but Not by Lipid-depleted Apolipoproteins* , 2005, Journal of Biological Chemistry.
[114] J. Glomset,et al. The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.
[115] A. Kontush,et al. Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[116] S. Goldstein,et al. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. , 1981, Journal of lipid research.
[117] T. Shioda,et al. MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis , 2010, Science.
[118] Jan Albert Kuivenhoven,et al. Genetic variant of the scavenger receptor BI in humans. , 2011, The New England journal of medicine.
[119] Aaron N. Chang,et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. , 2011, The Journal of clinical investigation.
[120] A. Tall,et al. Increased Inflammatory Gene Expression in ABC Transporter–Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions , 2008, Circulation.
[121] P. Alaupovic. The concept of apolipoprotein-defined lipoprotein families and its clinical significance , 2003, Current atherosclerosis reports.
[122] A. Zwinderman,et al. Compromised LCAT Function Is Associated With Increased Atherosclerosis , 2005, Circulation.
[123] H. Brewer,et al. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. , 1997, Journal of lipid research.
[124] N. Weissman,et al. The year in intracoronary imaging. , 2010, JACC. Cardiovascular imaging.
[125] A. Kontush,et al. Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[126] Daniel S. Ory,et al. miR-33 links SREBP-2 induction to repression of sterol transporters , 2010, Proceedings of the National Academy of Sciences.
[127] F. Karpe,et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. , 1988, Journal of lipid research.
[128] R. Hegele,et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[129] H. Brewer,et al. LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[130] W. Annema,et al. Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport , 2011, Current atherosclerosis reports.
[131] J. Albers,et al. Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins Published, JLR Papers in Press, March 6, 2006. , 2006, Journal of Lipid Research.
[132] A. Tall,et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.
[133] K. Moore,et al. MiR-33 Contributes to the Regulation of Cholesterol Homeostasis , 2010, Science.
[134] D. Rader,et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. , 2003, The Journal of clinical investigation.
[135] C. Fielding,et al. A protein cofactor of lecithin:cholesterol acyltransferase. , 1972, Biochemical and biophysical research communications.
[136] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.
[137] D. Rader,et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. , 2007, The Journal of clinical investigation.
[138] A. Vaughan,et al. Phospholipid Transfer Protein Interacts with and Stabilizes ATP-binding Cassette Transporter A1 and Enhances Cholesterol Efflux from Cells* , 2003, Journal of Biological Chemistry.
[139] R. F. Hoyt,et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[140] M. Liu,et al. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. , 1993, The Journal of biological chemistry.
[141] J. Brady,et al. Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* , 2001, The Journal of Biological Chemistry.
[142] M. Reilly,et al. Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo , 2003, Circulation.
[143] A. Tall,et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.
[144] F. Grosveld,et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.